Table II.

Results of ELISPOT and tetramer assays before immunization and after three or four courses

Arm1Arm2Arm3Total
Pre (n = 31)Post 3–4 (n = 22)Pre (n = 28)Post 3–4 (n = 25)Pre (n = 31)Post 3–4 (n = 16)Pre (n = 90)Post 3–4 (n = 63)
ELISPOT assay Spots/105 PBMC
 <1027 (87%)4 (18%)23 (82%)7 (28%)30 (97%)1 (6%)80 (89%)12 (19%)
 10–1004 (13%)7 (32%)5 (18%)10 (40%)1 (3%)1 (6%)10 (11%)18 (29%)
 10–1,000010 (45%)08 (32%)014 (88%)032 (51%)
 >1,00001 (5%)000001 (2%)
Tetramer assay % CD8+ cells
 <0.1%30 (97%)6 (27%)28 (97%)9 (36%)28 (90%)2 (12%)86 (95%)17 (27%)
 0.1–1%1 (3%)3 (14%)1 (3%)4 (16%)2 (7%)04 (4%)7 (9%)
 1.1–10%08 (36%)09 (36%)1 (3%)11 (69%)1 (1%)28 (44%)
 >10%05 (23%)03 (12%)03 (19%)011 (17%)